Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index; 11 of the 26 sources its claims cite were checked for support.
Abstract
Compared to national figures, all disorders were associated with substantially lower life expectancy: 8.0 to 14.6 life years lost for men and 9.8 to 17.5 life years lost for women. Highest reductions were found for men with schizophrenia (14.6 years lost) and women with schizoaffective disorders (17.5 years lost).
Overview
CoChat Summary
TL;DR
Using a large South London mental health case register linked to national mortality data, the paper estimates markedly reduced life expectancy at birth for people with serious mental illness and related disorders. The largest losses were 14.6 years for men with schizophrenia and 17.5 years for women with schizoaffective disorder.
Key findings
- Among 31,719 eligible people aged 15+ with SMI, 1,370 died during 2007–09.
- Compared with national figures, all disorders were associated with 8.0 to 14.6 life years lost for men and 9.8 to 17.5 life years lost for women.
- The greatest reductions were 14.6 years lost for men with schizophrenia and 17.5 years lost for women with schizoaffective disorders.
- In the analyzed sample, life expectancy at birth ranged from 62.8 years (men with schizophrenia) to 69.4 years (men with schizoaffective disorder), and from 64.1 years (women with schizoaffective disorder) to 74.4 years (women with depressive disorders).
Methods
- Retrospective register-based analysis using the SLAM Case Register Interactive Search (CRIS), a secondary mental health care database covering southeast London.
- Included people diagnosed before end-2009 with schizophrenia, schizoaffective disorder, bipolar disorder, substance use disorder, depressive episode, or recurrent depressive disorder and under active review during 2007–09; final analytic sample was 31,719 people aged 15+.
- Estimated life expectancy at birth by gender and diagnosis using national mortality returns (2007–09) and Chiang’s abridged life table method in 5-year age groups.
Limitations
- The authors state that the secondary healthcare setting may limit generalizability, especially for substance use disorders and depressive disorders, because register cases are likely a more severe and unrepresentative subset of community cases.
- Diagnostic categories overlapped, but the study analyzed disorders separately; the paper says comorbidity between SMI and substance use disorders should not be assumed to be captured because source data reflected primary diagnoses rather than co-occurrence.
- Evident from the text: the study uses administrative/register data and compares to national norms, so it cannot fully disentangle causal pathways or all confounding factors behind the mortality differences.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 10 Not checked · 19 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Despite healthcare improvements, there has been little evidence of benefit on life expectancy in people with SMI [1], [20], [21]”
§ Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London > Introduction Concerns about premature mortality among people with mental disorders have been increasing [1]–[6]. Higher general and specific causes of mortality in all or specific age groups have been identified for people with serious mental illnesses (SMI, which might include schizophrenia, schizoaffective disorder, bipolar disorder, and depressive psychosis) in a range of settings [1], [2], [7]–[11], although most report relative risks or rates of mortality rather than life expectancy – which is arguably a more important index for shaping policy since it takes premature mortality into account and has been widely used for other risk exposures such as smoking, diabetes, obesity, ethnicity and socioeconomic status [12]–[17]. Of the few studies to measure this outcome, clients with SMI from public mental health agencies in eight US states from 1997 to 2000 were found to have lower life expectancies of 13 to more than 30 years compared to the general population (depending on the year and state) [2], and a loss of 8.8 life years (14.1 years for men and 5.7 years for women) was estimated in a comparison between people treated for SMI and the general population in Massachusetts, US [1]. A Swedish study using a nationwide hospital discharge registry reported substantial gaps in life expectancy at age 30 for main mental disorder categories compared to the general population, particularly for functional psychosis other than schizophrenia / affective psychosis (15.9 years lost), substance abuse (15.6 years lost), and organic psychosis (14.8 years lost) among men and organic psychosis (22.6 years lost), mental retardation (14.7 years lost), and substance abuse (18.8 years lost) among women [18]. Preliminary strategies for preventing premature deaths among people with SMI have been suggested, emphasizing the management of suicide risk and physical illness, minimum polypharmacy, and improvement of accessibility to physical health care [19]. Despite healthcare improvements, there has been little evidence of benefit on life expectancy in people with SMI [1], [20], [21], and further research is urgently required [22]. We reported excess mortality for people with diagnoses of SMI, as well as for depressive and substance use disorders, drawing on data from the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register, which covers comprehensive secondary mental healthcare provision to a large geographically defined community, by standardized mortality ratios (SMRs) [23]. Nonetheless, equal weighting is used for each age group in the calculation of SMRs, which is insufficient for highlighting the impact of premature mortality among younger age groups in the study cohort.
What the sources say
- Not checked — no full text of the sourcecites [1] BP Dembling, 1999, Life expectancy and causes of death in a population treated for serious mental illness., Psychiatr Serv source
- Supportedcites [20] R Gray, 2009, Physical health and severe mental illness: if we don't do something about it, who will?, Int J Ment Health Nurs source
The opening discussion states that life expectancy for people with severe mental illness is decreasing, supporting the claim that it has shown little benefit. The discussion of interventions describes improvements in physical-health risk factors but says only a minority of patients receive them. Page numbers are not provided in our copy. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [21] LA Chwastiak, 2009, The unchanging mortality gap for people with schizophrenia., Lancet source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, in a sensitivity analysis of SMR data, the use of London comparators did not meaningfully change findings [23].”
§ Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London > Discussion Using a large secondary mental healthcare database in southeast London linked to national mortality returns, we confirmed substantially shortened life expectancies at birth for all serious mental disorder groups investigated compared to national norms. Largest reductions were found for men with schizophrenia, women with schizoaffective disorders, and both men and women with substance use disorders. In previous analyses of these cohorts, raised standardised mortality ratios (SMRs) had been described [23], although the picture was less dramatic because SMRs reflect less well the impact of premature mortality at earlier life stages. In a US study conducted by the Massachusetts Department of Mental Health from 1989 to 1994, service users with SMI were found to have lost 8.8 years of potential life (14.1 years for men and 5.7 for women) on average compared to the general population, a stronger impact for men and weaker impact for women compared to findings from our sample. However, SMI was not specifically defined in the Massachusetts study other than stating “evidence of serious dysfunction” as an inclusion criterion [1], which might explain the discrepancy. A Swedish analysis of national discharges from 1978–82 reported more complex data on life expectations at given ages. For the lowest age described (30 years), subsequent life expectancy associated with schizophrenia was 7.9 years lower in men and 9.5 years lower in women [18] – i.e. similar to the finding for women in our sample but less strong for men. Further international research is clearly required to compare the potential impacts of SMI on life expectancy in different settings since this may provide clues as to systems of care which may help to maximise this. Mortality in SMI is recognised to be raised and underlying causes may be multiple. As well as our own findings, any psychiatric diagnosis was associated with a 65% higher than expected total mortality in a case register study in a British primary care cohort [30]. In the same setting, a three-fold elevated mortality was found for coronary heart disease in young adults with SMI, and a more than two-fold increased mortality of stroke in all age groups [8]. Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3], [19], [20], [22], [31]–[33] and clearly need higher levels of consideration in order to improve health and survival, as well as the better-known risks of suicide and violent deaths. Because the causal pathways between mental disorder and premature mortality are multiple, and because life years lost as an outcome measures not only the effect of an exposure on risk of mortality but also its differential effect across the age range, it is difficult to interpret with certainty the gender variation in findings – i.e. the strongest effects of schizophrenia in men and schizoaffective disorder in women. Clearly the two disorders overlap substantially at a genetic and biological level. It is possible that the impact of co-occurring affective disorder is stronger in women due to specific biological or social vulnerability. However, against this, there was no difference in the impact of bipolar disorder between men and women and the impact of depressive episode/disorder was stronger in men. Alternative explanations may lie in the clinical practice of assigning diagnoses and gender differences here – for example, if there was preferential inclusion in women of severe personality disorders with transient psychotic episodes within this diagnostic group. Further research is clearly required to clarify this issue. Life expectancy is a commonly used indicator for how longevity may be impaired by specific long-term exposures (e.g. smoking, obesity, ethnicity, and socioeconomic status) or chronic states of ill-health or risk (e.g. diabetes mellitus) [12], [13], [15]–[17], [34], and provides an alternative platform to discriminate the influences of different exposures for the purpose of highlighting premature mortality at younger ages in potentially vulnerable groups [25]. It is therefore primarily a measure of impact and should be seen as complementary to more common studies using measures of effect, such as SMR statistics. As a measure, life expectancy analyses provide an important means of communicating impact on survival to policy makers and lay audiences. This approach also allows the impact of different exposures to be compared in a way which cannot be inferred from SMR outputs. As a case in point, considering the impact of other well-recognised exposures and comparing these with the potential impact of SMI, in a Japanese study of life expectancy from age 40, smoking was the most important predictor of six lifestyle related exposures (smoking, alcohol consumption, walking duration, sleep duration, consumption of green leafy vegetables, and obesity), current smoking being associated with around four to five life years lost for both genders [12], [13]. Considering 2005 life expectancy levels in the USA (75.1 years for men and 80.3 years for women), current and previous smoking was associated with 2.5 years lower life expectancy for men and 1.8 years lower life expectancy for women [17]. For British doctors born in 1900–1930 and followed up for fifty years, continued smoking was associated with around 10 years life lost, compared to lifelong non-smokers [16], and in New Zealand Census records in 1996, the gap in life expectancy between current and never smokers was 7.6 years in men and 6.7 for women [15]. Diabetes was reported to reduce life expectancy at age 15 by 1.3 years for men and 2.0 years for women in Canada [14], and a BMI of 40–45 kg/m2 was associated with a 10 year reduction of life expectancy at age 35 compared to a BMI 22.5–25 kg/m2 [35]. The potential impact of having a serious mental illness (or a substance use disorder or a depressive episode requiring secondary care contact) on life expectancy is therefore at least comparable and at worse substantially higher than effects of individual well-recognised exposures, although clearly the mechanisms through which mental disorders are associated with premature mortality will include the effects of these individual risk factors (for example, smoking behaviour, risk of diabetes, etc.) as well as other factors (such as risk of suicide or accidents and direct effects of mental distress on cardiovascular risk). Excess mortality associated with mental disorders has been demonstrated to be predominantly due to ‘natural’ causes [3], [5], [30], [31], [36]–[38], although mental health service provision is often focused on preventing more rare outcomes of suicide and violent death [39]–[41]. If improving overall survival is to be considered as an alternative priority, much more efforts are clearly required to address the challenges of improving general health in people with mental disorders through medical services, socioeconomic support, and physical health promotion strategies [19]. Strengths of the study described include the large sample size and nationwide coverage of mortality, as well as the context of complete electronic clinical records. Potential limitations include the secondary healthcare setting; this should present no problem for high penetrance disorders, such as schizophrenia and bipolar disorder, where most cases will have received secondary care input. However, findings for substance use disorders and depressive disorders should be viewed with circumspection since those appearing on a secondary care register are likely to be an unrepresentative (and probably more severe) subset of community cases. Ultimately, the findings for life expectancy should be taken as referring to people with these mental disorders who had made contact with secondary mental health services within the given time period and are not necessarily applicable to all cases in a given community. Diagnostic categories overlapped, but only a minority (5.7%) of people had received more than one mental disorder diagnosis during the surveillance period. Nevertheless, comorbidity between SMI and substance use disorders should not be assumed to be captured as the source data reflected primary diagnoses rather than co-occurrence. Also we did not attempt to capture co-occurring or changing diagnoses which present potentially complex issues for analysis in a secondary care sample and which we felt were beyond the scope of this initial report. Although SLAM is a major academic as well as clinical centre, mental disorders on the Case Register are likely to be broadly generalizable to other urban settings in the UK (the SLAM catchment covers a range of residence areas from inner city to suburban settings but does not include any rural areas). Life expectancy comparisons of regional data to national norms may be problematic. However, in a sensitivity analysis of SMR data, the use of London comparators did not meaningfully change findings [23]. Also, from administrative data, life expectancy at birth for population of the four catchment area boroughs in 2007–09 (ranging from 76.3–79.5 years for males and 81.1–82.9 years for females), were not substantially different to national estimates [42]. Our results demonstrate the substantial impact of serious mental illness on life expectancy and highlight importance of developing strategies to prevent premature mortality among people with SMI and other major mental disorders. Although the prevention of suicides and violent deaths are likely to be an important component, other causes of excess mortality should not be ignored, including cardiovascular diseases, cancer, and diabetes [3], [4], [7], [8], [22], [31]. Physical health risk assessments and assertive intervention by primary and secondary medical services have been proposed and have resulted in improvements [20], [43]. Continued monitoring of mortality trends in people with mental disorders will be required to evaluate the impact of policy changes as they occur.
What the sources say
- Supportedcites [23] CK Chang, 2010, All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study., BMC Psychiatry source
The Results report that SMRs standardized using London mortality data were comparable to those using England and Wales data. The Discussion states that this sensitivity analysis did not reveal any meaningful differences. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Excess mortality associated with mental disorders has been demonstrated to be predominantly due to ‘natural’ causes [3], [5], [30], [31], [36]–[38]”
§ Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London > Discussion Using a large secondary mental healthcare database in southeast London linked to national mortality returns, we confirmed substantially shortened life expectancies at birth for all serious mental disorder groups investigated compared to national norms. Largest reductions were found for men with schizophrenia, women with schizoaffective disorders, and both men and women with substance use disorders. In previous analyses of these cohorts, raised standardised mortality ratios (SMRs) had been described [23], although the picture was less dramatic because SMRs reflect less well the impact of premature mortality at earlier life stages. In a US study conducted by the Massachusetts Department of Mental Health from 1989 to 1994, service users with SMI were found to have lost 8.8 years of potential life (14.1 years for men and 5.7 for women) on average compared to the general population, a stronger impact for men and weaker impact for women compared to findings from our sample. However, SMI was not specifically defined in the Massachusetts study other than stating “evidence of serious dysfunction” as an inclusion criterion [1], which might explain the discrepancy. A Swedish analysis of national discharges from 1978–82 reported more complex data on life expectations at given ages. For the lowest age described (30 years), subsequent life expectancy associated with schizophrenia was 7.9 years lower in men and 9.5 years lower in women [18] – i.e. similar to the finding for women in our sample but less strong for men. Further international research is clearly required to compare the potential impacts of SMI on life expectancy in different settings since this may provide clues as to systems of care which may help to maximise this. Mortality in SMI is recognised to be raised and underlying causes may be multiple. As well as our own findings, any psychiatric diagnosis was associated with a 65% higher than expected total mortality in a case register study in a British primary care cohort [30]. In the same setting, a three-fold elevated mortality was found for coronary heart disease in young adults with SMI, and a more than two-fold increased mortality of stroke in all age groups [8]. Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3], [19], [20], [22], [31]–[33] and clearly need higher levels of consideration in order to improve health and survival, as well as the better-known risks of suicide and violent deaths. Because the causal pathways between mental disorder and premature mortality are multiple, and because life years lost as an outcome measures not only the effect of an exposure on risk of mortality but also its differential effect across the age range, it is difficult to interpret with certainty the gender variation in findings – i.e. the strongest effects of schizophrenia in men and schizoaffective disorder in women. Clearly the two disorders overlap substantially at a genetic and biological level. It is possible that the impact of co-occurring affective disorder is stronger in women due to specific biological or social vulnerability. However, against this, there was no difference in the impact of bipolar disorder between men and women and the impact of depressive episode/disorder was stronger in men. Alternative explanations may lie in the clinical practice of assigning diagnoses and gender differences here – for example, if there was preferential inclusion in women of severe personality disorders with transient psychotic episodes within this diagnostic group. Further research is clearly required to clarify this issue. Life expectancy is a commonly used indicator for how longevity may be impaired by specific long-term exposures (e.g. smoking, obesity, ethnicity, and socioeconomic status) or chronic states of ill-health or risk (e.g. diabetes mellitus) [12], [13], [15]–[17], [34], and provides an alternative platform to discriminate the influences of different exposures for the purpose of highlighting premature mortality at younger ages in potentially vulnerable groups [25]. It is therefore primarily a measure of impact and should be seen as complementary to more common studies using measures of effect, such as SMR statistics. As a measure, life expectancy analyses provide an important means of communicating impact on survival to policy makers and lay audiences. This approach also allows the impact of different exposures to be compared in a way which cannot be inferred from SMR outputs. As a case in point, considering the impact of other well-recognised exposures and comparing these with the potential impact of SMI, in a Japanese study of life expectancy from age 40, smoking was the most important predictor of six lifestyle related exposures (smoking, alcohol consumption, walking duration, sleep duration, consumption of green leafy vegetables, and obesity), current smoking being associated with around four to five life years lost for both genders [12], [13]. Considering 2005 life expectancy levels in the USA (75.1 years for men and 80.3 years for women), current and previous smoking was associated with 2.5 years lower life expectancy for men and 1.8 years lower life expectancy for women [17]. For British doctors born in 1900–1930 and followed up for fifty years, continued smoking was associated with around 10 years life lost, compared to lifelong non-smokers [16], and in New Zealand Census records in 1996, the gap in life expectancy between current and never smokers was 7.6 years in men and 6.7 for women [15]. Diabetes was reported to reduce life expectancy at age 15 by 1.3 years for men and 2.0 years for women in Canada [14], and a BMI of 40–45 kg/m2 was associated with a 10 year reduction of life expectancy at age 35 compared to a BMI 22.5–25 kg/m2 [35]. The potential impact of having a serious mental illness (or a substance use disorder or a depressive episode requiring secondary care contact) on life expectancy is therefore at least comparable and at worse substantially higher than effects of individual well-recognised exposures, although clearly the mechanisms through which mental disorders are associated with premature mortality will include the effects of these individual risk factors (for example, smoking behaviour, risk of diabetes, etc.) as well as other factors (such as risk of suicide or accidents and direct effects of mental distress on cardiovascular risk). Excess mortality associated with mental disorders has been demonstrated to be predominantly due to ‘natural’ causes [3], [5], [30], [31], [36]–[38], although mental health service provision is often focused on preventing more rare outcomes of suicide and violent death [39]–[41]. If improving overall survival is to be considered as an alternative priority, much more efforts are clearly required to address the challenges of improving general health in people with mental disorders through medical services, socioeconomic support, and physical health promotion strategies [19]. Strengths of the study described include the large sample size and nationwide coverage of mortality, as well as the context of complete electronic clinical records. Potential limitations include the secondary healthcare setting; this should present no problem for high penetrance disorders, such as schizophrenia and bipolar disorder, where most cases will have received secondary care input. However, findings for substance use disorders and depressive disorders should be viewed with circumspection since those appearing on a secondary care register are likely to be an unrepresentative (and probably more severe) subset of community cases. Ultimately, the findings for life expectancy should be taken as referring to people with these mental disorders who had made contact with secondary mental health services within the given time period and are not necessarily applicable to all cases in a given community. Diagnostic categories overlapped, but only a minority (5.7%) of people had received more than one mental disorder diagnosis during the surveillance period. Nevertheless, comorbidity between SMI and substance use disorders should not be assumed to be captured as the source data reflected primary diagnoses rather than co-occurrence. Also we did not attempt to capture co-occurring or changing diagnoses which present potentially complex issues for analysis in a secondary care sample and which we felt were beyond the scope of this initial report. Although SLAM is a major academic as well as clinical centre, mental disorders on the Case Register are likely to be broadly generalizable to other urban settings in the UK (the SLAM catchment covers a range of residence areas from inner city to suburban settings but does not include any rural areas). Life expectancy comparisons of regional data to national norms may be problematic. However, in a sensitivity analysis of SMR data, the use of London comparators did not meaningfully change findings [23]. Also, from administrative data, life expectancy at birth for population of the four catchment area boroughs in 2007–09 (ranging from 76.3–79.5 years for males and 81.1–82.9 years for females), were not substantially different to national estimates [42]. Our results demonstrate the substantial impact of serious mental illness on life expectancy and highlight importance of developing strategies to prevent premature mortality among people with SMI and other major mental disorders. Although the prevention of suicides and violent deaths are likely to be an important component, other causes of excess mortality should not be ignored, including cardiovascular diseases, cancer, and diabetes [3], [4], [7], [8], [22], [31]. Physical health risk assessments and assertive intervention by primary and secondary medical services have been proposed and have resulted in improvements [20], [43]. Continued monitoring of mortality trends in people with mental disorders will be required to evaluate the impact of policy changes as they occur.
What the sources say
- Supportedcites [3] A Fagiolini, 2009, The effects of undertreated chronic medical illnesses in patients with severe mental disorders., J Clin Psychiatry source
The Cardiovascular Disease section reports that approximately 59% of excess deaths in a meta-analysis of patients with schizophrenia were attributed to natural causes. The FOR CLINICAL USE section also reports that most excess deaths in a study of patients with bipolar disorder were due to natural causes. These findings support the cited background statement, particularly for the severe mental disorders the paper discusses. (LLM, conf=0.88)
- Partly supportedcites [5] S Brown, 2000, Causes of the excess mortality of schizophrenia., Br J Psychiatry sourceExperimental — accuracy not yet measured
The Natural cause mortality section reports that natural causes accounted for 63% of excess mortality, and Overall mortality says about two-thirds of extra deaths were from natural causes. The study concerns people with schizophrenia; it does not establish the same predominance across mental disorders generally. Page numbers are not provided in the supplied passages. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [30] DN Baxter, 1996, The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality., Br J Psychiatry source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3], [19], [20], [22], [31]–[33]”
§ Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London > Discussion Using a large secondary mental healthcare database in southeast London linked to national mortality returns, we confirmed substantially shortened life expectancies at birth for all serious mental disorder groups investigated compared to national norms. Largest reductions were found for men with schizophrenia, women with schizoaffective disorders, and both men and women with substance use disorders. In previous analyses of these cohorts, raised standardised mortality ratios (SMRs) had been described [23], although the picture was less dramatic because SMRs reflect less well the impact of premature mortality at earlier life stages. In a US study conducted by the Massachusetts Department of Mental Health from 1989 to 1994, service users with SMI were found to have lost 8.8 years of potential life (14.1 years for men and 5.7 for women) on average compared to the general population, a stronger impact for men and weaker impact for women compared to findings from our sample. However, SMI was not specifically defined in the Massachusetts study other than stating “evidence of serious dysfunction” as an inclusion criterion [1], which might explain the discrepancy. A Swedish analysis of national discharges from 1978–82 reported more complex data on life expectations at given ages. For the lowest age described (30 years), subsequent life expectancy associated with schizophrenia was 7.9 years lower in men and 9.5 years lower in women [18] – i.e. similar to the finding for women in our sample but less strong for men. Further international research is clearly required to compare the potential impacts of SMI on life expectancy in different settings since this may provide clues as to systems of care which may help to maximise this. Mortality in SMI is recognised to be raised and underlying causes may be multiple. As well as our own findings, any psychiatric diagnosis was associated with a 65% higher than expected total mortality in a case register study in a British primary care cohort [30]. In the same setting, a three-fold elevated mortality was found for coronary heart disease in young adults with SMI, and a more than two-fold increased mortality of stroke in all age groups [8]. Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3], [19], [20], [22], [31]–[33] and clearly need higher levels of consideration in order to improve health and survival, as well as the better-known risks of suicide and violent deaths. Because the causal pathways between mental disorder and premature mortality are multiple, and because life years lost as an outcome measures not only the effect of an exposure on risk of mortality but also its differential effect across the age range, it is difficult to interpret with certainty the gender variation in findings – i.e. the strongest effects of schizophrenia in men and schizoaffective disorder in women. Clearly the two disorders overlap substantially at a genetic and biological level. It is possible that the impact of co-occurring affective disorder is stronger in women due to specific biological or social vulnerability. However, against this, there was no difference in the impact of bipolar disorder between men and women and the impact of depressive episode/disorder was stronger in men. Alternative explanations may lie in the clinical practice of assigning diagnoses and gender differences here – for example, if there was preferential inclusion in women of severe personality disorders with transient psychotic episodes within this diagnostic group. Further research is clearly required to clarify this issue. Life expectancy is a commonly used indicator for how longevity may be impaired by specific long-term exposures (e.g. smoking, obesity, ethnicity, and socioeconomic status) or chronic states of ill-health or risk (e.g. diabetes mellitus) [12], [13], [15]–[17], [34], and provides an alternative platform to discriminate the influences of different exposures for the purpose of highlighting premature mortality at younger ages in potentially vulnerable groups [25]. It is therefore primarily a measure of impact and should be seen as complementary to more common studies using measures of effect, such as SMR statistics. As a measure, life expectancy analyses provide an important means of communicating impact on survival to policy makers and lay audiences. This approach also allows the impact of different exposures to be compared in a way which cannot be inferred from SMR outputs. As a case in point, considering the impact of other well-recognised exposures and comparing these with the potential impact of SMI, in a Japanese study of life expectancy from age 40, smoking was the most important predictor of six lifestyle related exposures (smoking, alcohol consumption, walking duration, sleep duration, consumption of green leafy vegetables, and obesity), current smoking being associated with around four to five life years lost for both genders [12], [13]. Considering 2005 life expectancy levels in the USA (75.1 years for men and 80.3 years for women), current and previous smoking was associated with 2.5 years lower life expectancy for men and 1.8 years lower life expectancy for women [17]. For British doctors born in 1900–1930 and followed up for fifty years, continued smoking was associated with around 10 years life lost, compared to lifelong non-smokers [16], and in New Zealand Census records in 1996, the gap in life expectancy between current and never smokers was 7.6 years in men and 6.7 for women [15]. Diabetes was reported to reduce life expectancy at age 15 by 1.3 years for men and 2.0 years for women in Canada [14], and a BMI of 40–45 kg/m2 was associated with a 10 year reduction of life expectancy at age 35 compared to a BMI 22.5–25 kg/m2 [35]. The potential impact of having a serious mental illness (or a substance use disorder or a depressive episode requiring secondary care contact) on life expectancy is therefore at least comparable and at worse substantially higher than effects of individual well-recognised exposures, although clearly the mechanisms through which mental disorders are associated with premature mortality will include the effects of these individual risk factors (for example, smoking behaviour, risk of diabetes, etc.) as well as other factors (such as risk of suicide or accidents and direct effects of mental distress on cardiovascular risk). Excess mortality associated with mental disorders has been demonstrated to be predominantly due to ‘natural’ causes [3], [5], [30], [31], [36]–[38], although mental health service provision is often focused on preventing more rare outcomes of suicide and violent death [39]–[41]. If improving overall survival is to be considered as an alternative priority, much more efforts are clearly required to address the challenges of improving general health in people with mental disorders through medical services, socioeconomic support, and physical health promotion strategies [19]. Strengths of the study described include the large sample size and nationwide coverage of mortality, as well as the context of complete electronic clinical records. Potential limitations include the secondary healthcare setting; this should present no problem for high penetrance disorders, such as schizophrenia and bipolar disorder, where most cases will have received secondary care input. However, findings for substance use disorders and depressive disorders should be viewed with circumspection since those appearing on a secondary care register are likely to be an unrepresentative (and probably more severe) subset of community cases. Ultimately, the findings for life expectancy should be taken as referring to people with these mental disorders who had made contact with secondary mental health services within the given time period and are not necessarily applicable to all cases in a given community. Diagnostic categories overlapped, but only a minority (5.7%) of people had received more than one mental disorder diagnosis during the surveillance period. Nevertheless, comorbidity between SMI and substance use disorders should not be assumed to be captured as the source data reflected primary diagnoses rather than co-occurrence. Also we did not attempt to capture co-occurring or changing diagnoses which present potentially complex issues for analysis in a secondary care sample and which we felt were beyond the scope of this initial report. Although SLAM is a major academic as well as clinical centre, mental disorders on the Case Register are likely to be broadly generalizable to other urban settings in the UK (the SLAM catchment covers a range of residence areas from inner city to suburban settings but does not include any rural areas). Life expectancy comparisons of regional data to national norms may be problematic. However, in a sensitivity analysis of SMR data, the use of London comparators did not meaningfully change findings [23]. Also, from administrative data, life expectancy at birth for population of the four catchment area boroughs in 2007–09 (ranging from 76.3–79.5 years for males and 81.1–82.9 years for females), were not substantially different to national estimates [42]. Our results demonstrate the substantial impact of serious mental illness on life expectancy and highlight importance of developing strategies to prevent premature mortality among people with SMI and other major mental disorders. Although the prevention of suicides and violent deaths are likely to be an important component, other causes of excess mortality should not be ignored, including cardiovascular diseases, cancer, and diabetes [3], [4], [7], [8], [22], [31]. Physical health risk assessments and assertive intervention by primary and secondary medical services have been proposed and have resulted in improvements [20], [43]. Continued monitoring of mortality trends in people with mental disorders will be required to evaluate the impact of policy changes as they occur.
What the sources say
- Partly supportedcites [3] A Fagiolini, 2009, The effects of undertreated chronic medical illnesses in patients with severe mental disorders., J Clin Psychiatry sourceExperimental — accuracy not yet measured
The Medication Side Effects section says atypical antipsychotics increase the likelihood of cardiovascular disease, and the lifestyle discussion links inactivity, poor diet, and smoking to coronary heart disease. Our copy does not establish a risk specifically from long-term antipsychotic use or address illicit drug use as a cardiovascular risk factor; it discusses cardiovascular disease rather than cardiovascular events specifically. Page numbers were not available in our copy. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [19] P Auquier, 2006, Mortality in schizophrenia., Pharmacoepidemiol Drug Saf source
- Partly supportedcites [20] R Gray, 2009, Physical health and severe mental illness: if we don't do something about it, who will?, Int J Ment Health Nurs sourceExperimental — accuracy not yet measured
In “Why then do our patients die?” (page not provided), Gray identifies obesity, smoking, lack of exercise and poor diet as prevalent lifestyle risks in people with severe mental illness, and says some prescribed medications increase cardiometabolic disease risk. The passage does not specify long-term antipsychotic use or link illicit drug use to cardiovascular events; it mentions drug misuse only as another influence on health. (LLM, conf=0.85)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All the life expectancies at birth for specific mental disorders were significantly different between genders based on their 95% confidence intervals.”
§ Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
6 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“people with mental health disorders have a life expectancy eight years less than the general population”
From Change in mental health after smoking cessation: systematic review and meta-analysis (2014) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reductions of life expectancy among persons with bipolar disorder seem to be slightly smaller: approximately 10 years in a study from London [43], and 13 years in a Danish study made on data similar to the Danish data used in Table 3 [44].”
From Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. (2013) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This mortality gap translates to a 10-20 year shortened life expectancy 3,4”
From Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This mortality gap translates into a 10-20 year shortened life expectancy (3,4) and appears to be widening (5).”
From Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis (2015) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent study from the United Kingdom (Chang et al. 2011) found that life expectancy was reduced by 14.6 years among persons with schizophrenia.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Chang et al. 2011
Experimental — accuracy not yet measured
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“. For British doctors born in 1900–1930 and followed up for fifty years, continued smoking was associated with around 10 years life lost, compared to lifelong non-smokers”
BackgroundSchizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Excess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881 · cited 1×
“Although the prevention of suicides and violent deaths are likely to be an important component, other causes of excess mortality should not be ignored, including cardiovascular diseases, cancer, and diabetes [3,4,7,8,22,31].”
Background(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087 · cited 2×
“Excess mortality associated with mental disorders has been demonstrated to be predominantly due to ‘natural’ causes [3,5,30,31,36–38], although mental health service provision is often focused on preventing more rare outcomes of suicide and violent death [39–41].”
BackgroundDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
The unhealthy lifestyle of people with schizophrenia
BROWN, S., BIRTWISTLE, J., ROE, L., & THOMPSON, C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008186 · Cited by 874 · cited 1×
“obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3,19,20,22,31–33] and clearly need higher levels of consideration in order to improve health and survival, as well as the better-known risks of suicide and violent dea…”
Background
Cited by
Items 101–200 of 706
Godin, O., Collaborators, F. T. F. A. C. O. E. I. B. D. (.-B., Etain, B., Henry, C., Bougerol, T., Courtet, P., Mayliss, L., Passerieux, C., Azorin, J.-M., Kahn, J.-P., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09038 · Cited by 60
Lawrence, D., & Williams, J. M. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv272 · Cited by 60
Bone density and depressive disorder: a meta‐analysis
Schweiger, J. U., Schweiger, U., Hüppe, M., Kahl, K. G., Greggersen, W., & Fassbinder, E. (2016) · Brain and Behavior · doi:10.1002/brb3.489 · Cited by 60
“The finding is of considerable importance, as osteoporosis and osteoporotic fractures may constitute a partial explanation for the increased mortality and decreased life expectancy in patients with severe mental disorders (Chang et al. 2011).”
BackgroundImpact of socioeconomic deprivation on rate and cause of death in severe mental illness
Martin, J. L., McLean, G., Park, J. B., Martin, D. J., Connolly, M., Mercer, S. W., & Smıth, D. J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0261-4 · Cited by 64
“Furthermore, there is recent evidence from the UK [12], US [13] and Western Australia [14] to suggest that this mortality gap may be getting worse.”
BackgroundData science for mental health: a UK perspective on a global challenge
McIntosh, A. M., Stewart, R., John, A., Smith, D. J., Davis, K., Sudlow, C., Corvin, A., Nicodemus, K. K., Kingdon, D., Hassan, L., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30089-x · Cited by 59
Self-citationExcess mortality and shortened life expectancy in people with major mental illnesses in Taiwan
Pan, Y., Yeh, L., Chan, H., & Chang, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000694 · Cited by 68
“8 years lost for women for patients with schizophrenia (Chang et al., 2011).”
Self-citationClozapine and incidence of myocarditis and sudden death – Long term Australian experience
Khan, A. A., Ashraf, A., Baker, D. W., Al-Omary, M. S., Savage, L., Ekmejian, A. A., Singh, R., Brienesse, S. C., Majeed, T., Gordon, T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.013 · Cited by 64
“[7-9] The possible explanations for higher mortality include poor functional status, substance abuse, and effects of psychotropic medications.”
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12054 · Cited by 66
“controls, with a reduction of >14 years for males, and 17 years for females (2).”
BackgroundAjetunmobi, O., Taylor, M., Stockton, D., & Wood, R. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002768 · Cited by 56
“55(12): 752-760 The Chang et al (2011) reference has been added – it is the most recent.”
BackgroundRide, J., Kasteridis, P., Gutacker, N., Aragón, M. J., & Jacobs, R. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00530-2 · Cited by 66
Obstructive sleep apnoea and schizophrenia — A research agenda
Kalucy, M. J., Grunstein, R., Lambert, T., & Glozier, N. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.10.003 · Cited by 55
Clinical correlates of vitamin D deficiency in established psychosis
Lally, J., Gardner-Sood, P., Firdosi, M., Iyegbe, C. O., Stubbs, B., Greenwood, K., Murray, R. M., Smith, S. M., Howes, O. D., & Gaughran, F. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0780-2 · Cited by 66
“This is particularly so, given that people with psychotic illnesses residing in the geographical area where this work was carried out, have a life span shortened by up to 18 years [37].”
BackgroundKodesh, A., Goldshtein, I., Gelkopf, M., Goren, I., Chodick, G., & Shalev, V. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-012-0478-9 · Cited by 53
“This was recently demonstrated in a study publication based on the electronic database of a large and comprehensive secondary mental health-care provider in London [42].”
BackgroundGlobal Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders
Patel, V., Chisholm, D., Parikh, R., Charlson, F. J., Degenhardt, L., Dua, T., Ferrari, A. J., Hyman, S., Laxminarayan, R., Levin, C., et al. (2016) · Disease Control Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders · doi:10.1596/978-1-4648-0426-7_ch1 · Cited by 53
Jia, H., & Lubetkin, E. I. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0582-8 · Cited by 55
“Depression can also be life threatening and has been associated with excess mortality and substantially lower life expectancy [6, 7].”
BackgroundFazal, K., Perera, G., Khondoker, M. R., Howard, R. J., & Stewart, R. J. (2017) · BJPsych Open · doi:10.1192/bjpo.bp.116.004184 · Cited by 58
Self-citationPerry, A., Lawrence, V., & Henderson, C. (2020) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.112974 · Cited by 51
Manago, B. N., Pescosolido, B. A., & Ólafsdóttir, S. (2018) · Scandinavian Journal of Public Health · doi:10.1177/1403494817750337 · Cited by 57
“[2] Chang C-K, Hayes RD, Perera G, et al.”
BackgroundAcute general hospital admissions in people with serious mental illness
Jayatilleke, N., Hayes, R. D., Chang, C., & Stewart, R. J. (2018) · Psychological Medicine · doi:10.1017/s0033291718000284 · Cited by 55
“2011), resulting in substantially higher mortality and shortened life expectancy (Chang et al. 2011; Lawrence et al. 2013).”
Self-citationHigher mortality and years of potential life lost of suicide in patients with schizophrenia
Ko, Y. S., Tsai, H.-C., Chi, M. H., Su, C.-C., Lee, I. H., Chen, P. S., Chen, K. C., & Yang, Y. K. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.038 · Cited by 51
for the HELPS Network, Park, A., McDaid, D., Weiser, P., von Gottberg, C., Becker, T. M., & Kilian, R. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-787 · Cited by 57
“6 years [28].”
McAneney, H., Tully, M. A., Hunter, R. F., Kouvonen, A. M., Veal, P., Stevenson, M., & Kee, F. (2015) · BMC Public Health · doi:10.1186/s12889-015-2590-8 · Cited by 58
“The temptation is to think only of physical health, but to do so would ignore the importance of mental health and mental well-being which, though often less visible, are themselves strong explanatory variables of physical health and longevity [41].”
BackgroundMonteith, S., Glenn, T., Geddes, J., Whybrow, P. C., & Bauer, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0051-7 · Cited by 50
“…bipolar disorder including the incidence, prevalence, decreased life expectancy (Munk-Jørgensen et al. 2014; Allebeck 2009; Laursen et al. 2007; Chang et al. 2011; Kessing et al. 2015c; Kes-sing et al. 2015d), and trends in prescribing medication (Baldessarini et al. 2007; Hayes et al. 2011;…”
BackgroundWerbeloff, N., Chang, C., Broadbent, M. T. M., Hayes, J., Stewart, R. J., & Osborn, D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30416-3 · Cited by 55
Self-citationDas‐Munshi, J., Ashworth, M. J., Dewey, M. E., Gaughran, F., Hull, S., Morgan, C., Nazroo, J. Y., Petersen, I., Schofield, P., Stewart, R. J., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13298 · Cited by 55
Self-citationWoodhead, C., Ashworth, M. J., Schofield, P., & Henderson, M. (2014) · BMC Family Practice · doi:10.1186/1471-2296-15-117 · Cited by 58
“This mortality gap has been estimated at 10–18 years for women and 8–19 years for men [2,4-6].”
BackgroundBlood cadmium and depressive symptoms in young adults (aged 20–39 years)
Scinicariello, F., & Buser, M. C. (2014) · Psychological Medicine · doi:10.1017/s0033291714001883 · Cited by 56
“2014), a finding that may help to overcome professional reluctance to intervene with smokers who have mental health problems (Johnson et al. 2010; Chang et al. 2011).”
BackgroundCancer and mental health—a clinical and research unmet need
Purushotham, A. D., Bains, S., Lewison, G., SZMUKLER, G. I., & Sullivan, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt214 · Cited by 55
Buser, M. C., & Scinicariello, F. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10383 · Cited by 56
Holt, R. I. G., Hind, D., Gossage-Worrall, R., Bradburn, M. J., Saxon, D. H., McCrone, P., Morris, T., Etherington, A., Shiers, D., Barnard-Kelly, K. D., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22650 · Cited by 56
“Criteria for inclusion in the Health Technology Assessment journal Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.”
BackgroundMethodInfluentialTechnology to assess and support self-management in serious mental illness
Depp, C. A., Moore, R. C., Perivoliotis, D., & Granholm, E. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.2/cdepp · Cited by 48
Jia, H., Zack, M. M., Gottesman, I. I., & Thompson, W. (2017) · Value in Health · doi:10.1016/j.jval.2017.08.002 · Cited by 52
Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Yalın, N., & Young, A. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s245166 · Cited by 54
Chui, Z., Gazard, B., MacCrimmon, S., Harwood, H., Downs, J. M., Bakolis, I., Polling, C., Rhead, R. D., & Hatch, S. L. (2020) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01603-7 · Cited by 69
Fröhlich, A. S., Gerstner, N., Gagliardi, M., Ködel, M., Yusupov, N., Matosin, N., Czamara, D., Sauer, S., Roeh, S., Murek, V., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01742-z · Cited by 66
“Psychiatric disorders, transdiagnostically, are associated with lower life expectancy 46 and an increased risk for neurodegenerative disorders 47 , which in turn is associated with an increased mortality rate 48 .”
BackgroundImproving Interprofessional Approaches to Physical and Psychiatric Comorbidities Through Simulation
Fernando, A., Attoe, C., Jaye, P., Cross, S., Pathan, J., & Wessely, S. C. (2017) · Clinical Simulation in Nursing · doi:10.1016/j.ecns.2016.12.004 · Cited by 54
Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom
Iwagami, M., Mansfield, K. E., Hayes, J., Walters, K. R., Osborn, D., Smeeth, L. L., Nitsch, D., & Tomlinson, L. A. (2018) · Clinical Epidemiology · doi:10.2147/clep.s154841 · Cited by 62
Álvarez-Mon, M. Á., Asúnsolo, Á., Fraile‐Μartinez, O., Quintero, J., Ferre, F., Pereira-Sánchez, V., Ortuño, F., & Álvarez‐Mon, M. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9582 · Cited by 55
“Furthermore, mortality is significantly higher among people with mental health disorders than it is among comparable populations, with a 10-year median of potential life lost [4,5].”
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 55
Klotho at the Edge of Alzheimer’s Disease and Senile Depression
Paroni, G., Panza, F., Cosmo, S. D., Greco, A., Seripa, D., & Mazzoccoli, G. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1200-z · Cited by 47
Bellass, S., Lister, J., Kitchen, C. E. W., Kramer, L., Alderson, S. L., Doran, T., Gilbody, S. M., Han, L., Hewitt, C. E., Holt, R. I. G., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14562 · Cited by 55
Whole-person care: from rhetoric to reality. Achieving parity between mental and physical health.
Bailey, S., Thorpe, L. N., & Smith, G. (2013) · Cited by 78
Chesney, E., Robson, D., Patel, R., Shetty, H., Richardson, S., Chang, C.-K., McGuire, P., & McNeill, A. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.09.006 · Cited by 45
Self-citationKadra-Scalzo, G., Stewart, R. J., Shetty, H., MacCabe, J. H., Chang, C., Taylor, D. M., & Hayes, R. D. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12906 · Cited by 45
“Patients with serious mental illnesses (SMI) have been estimated to die approximately 15 to 20 years earlier than the general population (1, 2).”
BackgroundSelf-citationParity of esteem between mental and physical health
Millard, C., & Wessely, S. C. (2014) · BMJ · doi:10.1136/bmj.g6821 · Cited by 56
Chang, W. C., Chan, J. K. N., Wong, C. S. M., Hai, J. S. H., Or, P. C. F., & Chen, E. Y. H. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa013 · Cited by 46
Cox, N., & Webb, L. (2015) · Sociology of Health & Illness · doi:10.1111/1467-9566.12230 · Cited by 45
Wu, S.-I., Chen, S.-C., Liu, S.-I., Sun, F.-J., Juang, J. J. M., Lee, H.-C., Kao, K.-L., Dewey, M. E., Prince, M., & Stewart, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134763 · Cited by 44
Self-citationPhysical health in severe mental illness
Ashworth, M. J., Schofield, P., & Das‐Munshi, J. (2017) · British Journal of General Practice · doi:10.3399/bjgp17x692621 · Cited by 55
Care Provision to Prevent Chronic Disease by Community Mental Health Clinicians
Bartlem, K. M., Bowman, J. A., Freund, M., Wye, P. M., McElwaine, K. M., Wolfenden, L., Campbell, E. M., Gillham, K. E., & Wiggers, J. H. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.08.003 · Cited by 43
Lamontagne-Godwin, F., Burgess, C. C., Clement, S., Gasston-Hales, M., Greene, C., Manyande, A., Taylor, D., Walters, P., & Barley, E. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019412 · Cited by 57
Bakolis, I., Stewart, R. J., Baldwin, D. S., Beenstock, J., Bibby, P. F., Broadbent, M. T. M., Cardinal, R. N., Chen, S., Chinnasamy, K., Cipriani, A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049721 · Cited by 47
Self-citationDregan, A., McNeill, A., Gaughran, F., Jones, P. B., Bazley, A., Cross, S., Lillywhite, K., Armstrong, D., Smith, S., Osborn, D. P. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230674 · Cited by 41
“Because younger people (<15 years of age) are unlikely to receive a diagnosis of SMI,[1] we have used the UK all-cause mortality rates for the under 18 year age group in substitution.”
BackgroundMethodInfluentialSelf-citationLemogne, C., Nabi, H., Melchior, M., Goldberg, M., Limosin, F., Consoli, S. M., & Zins, M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.015 · Cited by 43
Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis
Sengupta, S. M., MacDonald, K., Fathalli, F., Yim, A., Lepage, M., Iyer, S. N., MALLA, A. K., & Joober, R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.039 · Cited by 50
“…occurring during adolescence or early adulthood, psychotic disorders have serious long-term implications including reduced life expectancy (Chang et al., 2011), disruption of social and emotional development, education underachievement, unemployment (Switaj et al., 2012), and suicide (Hor…”
BackgroundWilliams, J., Stubbs, B., Richardson, S., Flower, C., Barr-Hamilton, L., Grey, B., Hubbard, K., Spaducci, G., Gaughran, F., & Craig, T. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2274-5 · Cited by 54
Döme, P., Kunovszki, P., Takács, P., Fehér, L., Balázs, T., Dede, K., Mulhern-Haughey, S., Barbreau, S., & Rihmer, Z. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245510 · Cited by 40
Bartlem, K. M., Bowman, J., Freund, M., Wye, P. M., Lecathelinais, C., McElwaine, K., Wolfenden, L., Gillham, K. E., & Wiggers, J. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400360 · Cited by 43
“of chronic disease morbidity and mortality (65,66) and of experiencing a reduced life expectancy (1,3,67), the finding that clients with a diagnosis of schizophrenia were less likely to receive care for alcohol consumption suggests that initiatives to increase the provision of such care for this client group are a par…”
BackgroundBailey, J. M., Bartlem, K. M., Wiggers, J., Wye, P. M., Stockings, E., Hodder, R. K., Metse, A. P., Regan, T. W., Clancy, R., Dray, J., et al. (2019) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2019.100969 · Cited by 45
Evins, A. E., West, R., Benowitz, N. L., Russ, C., Lawrence, D., McRae, T., Maravic, M. C., Heffner, J. L., & Anthenelli, R. M. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000032 · Cited by 39
Central levels of tryptophan metabolites in subjects with bipolar disorder
Trepci, A., Sellgren, C. M., Pålsson, E., Brundin, L., Khanlarkhani, N., Schwieler, L., Landén, M., & Erhardt, S. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.018 · Cited by 40
Blixen, C. E., Perzynski, A. T., Kanuch, S. W., Dawson, N. V., Kaiser, D., Lawless, M. E., Seeholzer, E. L., & Sajatovic, M. (2014) · Primary Health Care Research & Development · doi:10.1017/s1463423614000176 · Cited by 44
“between 9 and 32 years of life (Dembling et al., 1999; Miller et al., 2006; Chang et al., 2011; Lawrence et al., 2013).”
BackgroundHuang, H., Meller, W. H., Kishi, Y., & Kathol, R. G. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2014.964189 · Cited by 45
“The bidirectional model is a recent addition in the BH sector and has grown since the publication of early mortality results (Chang et al., 2011; Druss et al., 2011).”
BackgroundCircadian rhythms and sleep in bipolar disorder: implications for pathophysiology and treatment
Soreca, I. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000108 · Cited by 38
“Considering the wealth of data documenting CVD morbidity and mortality in bipolar disorder [42,43], there has been surprisingly little research investigating the causes and mechanisms, other than the reported effects of psychotropic medications on CVD risk.”
BackgroundPhysical Health and Drug Safety in Individuals with Schizophrenia
Pringsheim, T. M., Kelly, M. A., Urness, D., Teehan, M. D., Ismail, Z., & Gardner, D. M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717719898 · Cited by 46
Allostatic load and systemic comorbidities in psychiatric disorders
Finlay, S., Rudd, D., McDermott, B., & Sarnyai, Z. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105726 · Cited by 38
Bowers, L., Cullen, A. E., Achilla, E., Baker, J. A., Khondoker, M. R., Koeser, L., Moylan, L. B., Pettit, S., Quirk, A., Sethi, F. N., et al. (2017) · Health Services and Delivery Research · doi:10.3310/hsdr05210 · Cited by 49
“Risk factor Cases (N= 986), n (%) Controls (N= 994), n (%) Analyses Unadjusted Adjusted OR 95% CI p-value OR 95% CI p-value Age (years) ≥ 45 151 (15) 365 (37) 1 – – 1 – –”
Chan, V. K. Y., Leung, M. Y. M., Chan, S. S. M., Yang, D., Knapp, M. R. J., Luo, H., Craig, D., Chen, Y., Bishai, D. M., Wong, G. H. Y., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101026 · Cited by 63
Suetani, S., Rosenbaum, S., Scott, J. G., Curtis, J., & Ward, P. B. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015001043 · Cited by 42
“Since 2010, a range of studies from various countries, including the UK (Chang et al. 2011), the Nordic countries (Laursen, 2011; Laursen et al.”
BackgroundProspective associations between multiple lifestyle behaviors and depressive symptoms
Werneck, A. O., Vancampfort, D., Stubbs, B., da Silva, D. R. P., Cucato, G. G., Christófaro, D. G. D., Santos, R. D., Ritti‐Dias, R. M., & Bittencourt, M. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.131 · Cited by 42
“Depression reduces life expectancy by approximately 10 years (Chang et al., 2011), partly due to an increased risk for cardiovascular diseases (Correll et al.”
BackgroundThe Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial
Lally, J., Watkins, R., Nash, S., Shetty, H., Gardner-Sood, P., Smith, S., Murray, R. M., & Gaughran, F. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00654 · Cited by 36
“Mild to very severe problem 9 (1) 1(0.”
BackgroundSolmi, M., Koyanagi, A., Thompson, T., Fornaro, M., Correll, C. U., & Veronese, N. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579601800077x · Cited by 46
“A higher prevalence of diabetes has been observed compared with the general population in patients with severe mental illness (SMI) (R1.”
InfluentialFornaro, M., Solmi, M., Stubbs, B., Veronese, N., Monaco, F., Novello, S., Fusco, A., Anastasia, A., De Berardis, D., Carvalho, A. F., et al. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.5 · Cited by 35
Lêng, C. H., Chou, M. H., Lin, S., Yang, Y. K., & Wang, J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.033 · Cited by 35
Gruer, L. D., Cezard, G. I., Clark, E., Douglas, A., Steiner, M. F. C., Millard, A. D., Buchanan, D., Katikireddi, S. V., Sheikh, A., & Bhopal, R. S. (2016) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2016-207426 · Cited by 34
Kugathasan, P., Wu, H., Gaughran, F., Nielsen, R. E., Pritchard, M., Dobson, R., Stewart, R. J., & Stubbs, B. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.061 · Cited by 40
Self-citationDennison, C. A., Legge, S. E., Bracher‐Smith, M., Menzies, G. E., Escott‐Price, V., Smıth, D. J., Doherty, A., Owen, M. J., O’Donovan, M. C., & Walters, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249189 · Cited by 40
“This has important consequences for the physical health of those with psychiatric disorders, particularly as these individuals are known to be at greater risk of numerous physical health conditions [11] and early mortality [43], which may in part be due to reduced levels of activity.”
Cullen, A. E., Jewell, A., Tully, J., Coghlan, S., Dean, K., & Fahy, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138819 · Cited by 36
“The CRIS tool has been described in detail previously [16,17,18].”
MethodPoulton, A. S., Armstrong, B. K., & Nanan, R. K. H. (2018) · CNS Drugs · doi:10.1007/s40263-018-0505-9 · Cited by 40
Wykes, T., Joyce, E. M., Velikonja, T., Watson, A., Aarons, G. A., Birchwood, M. J., Cella, M., Dopson, S., Fowler, D. G., Greenwood, K., et al. (2018) · Trials · doi:10.1186/s13063-018-2553-3 · Cited by 37
“It is also associated with an average loss of life-span of up to 20 years [2], poor employment prospects and difficulty in achieving satisfying social relationships.”
Backgroundde la Cruz, L. F., Llorens, M., Jassi, A. D., Krebs, G., Vidal‐Ribas, P., Raduà, J., Hatch, S. L., Bhugra, D., Heyman, I., Clark, B., et al. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.154062 · Cited by 39
Seeman, M. V. (2012) · Women s Health · doi:10.2217/whe.11.97 · Cited by 47
“Standard mortality ratios in a recent study from England were twice as high in schizophrenia as in the general population and higher in women than in men [40,41].”
Solmi, M., Miola, A., Capone, F., Pallottino, S., Højlund, M., Firth, J., Siskind, D. J., Holt, R. I. G., Corbeil, O., Cortese, S., et al. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2396396 · Cited by 40
“People with schizophrenia and related disorders, bipolar disorder (BD) and major depressive disorder, i.e. severe mental illness (SMI), have a ≥ 2-fold mortality rate than in the general population [1–3], and approximately 10–20 years reduced life expectancy [4,5].”
Contours of Usual Care: Meeting the Medical Needs of Diverse People with Serious Mental Illness
Ezell, J. M., Siantz, E., & Cabassa, L. J. (2013) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2013.0158 · Cited by 33
Wu, C., Chang, C., Hayes, R. D., Broadbent, M. T. M., Hotopf, M. H., & Stewart, R. J. (2011) · Psychological Medicine · doi:10.1017/s0033291711002698 · Cited by 33
“Disorders such as schizophrenia and bipolar disorder are associated with profound reductions in life expectancy (Chang et al. 2011), which if anything are worsening rather than improving (Hoang et al. 2011).”
BackgroundSelf-citationRetzer, A., Sayers, R., Pinfold, V., Gibson, J., Keeley, T., Taylor, G. M. J., Plappert, H., Gibbons, B., Huxley, P. J., Mathers, J. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240518 · Cited by 34
Das‐Munshi, J., Stewart, R. J., Morgan, C., Nazroo, J. Y., Thornicroft, G., & Prince, M. J. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.159210 · Cited by 36
Self-citationCanal‐Rivero, M., López-Moríñigo, J.-D., Setién‐Suero, E., Ruíz-Veguilla, M., Ayuso‐Mateos, J. L., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.06.001 · Cited by 30
“6 years in people diagnosed with schizophrenia [2].”
BackgroundKesserwani, J., Kadra-Scalzo, G., Downs, J. M., Shetty, H., MacCabe, J. H., Taylor, D. M., Stewart, R. J., Chang, C., & Hayes, R. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118817387 · Cited by 30
“Schizophrenia and schizoaffective disorder are associated with a mortality risk 2–2.5 times greater than that of the general population (Chang et al., 2010) and increased physical morbidity, which is highlighted by a 10–20-year reduction in patient life expectancy (Chang et al., 2011).”
BackgroundInfluentialSelf-citationBartlem, K. M., Bowman, J., Freund, M., Wye, P. M., Barker, D., McElwaine, K., Wolfenden, L., Campbell, E. M., McElduff, P., Gillham, K. E., et al. (2015) · Implementation Science · doi:10.1186/s13012-016-0408-4 · Cited by 29
Werneck, A. O., Hoare, E., Stubbs, B., van Sluijs, E. M. F., & Corder, K. L. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106436 · Cited by 33
Life expectancy and potential years of life lost for schizophrenia in western China
Liu, X., Wang, D., Fan, R., Wang, R., Hu, X., Yang, X., & Liu, Y. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114330 · Cited by 32
Transdiagnostic evaluation of epigenetic age acceleration and burden of psychiatric disorders
Yusupov, N., Dieckmann, L., Erhart, M., Sauer, S., Rex‐Haffner, M., Kopf‐Beck, J., Brückl, T. M., Czamara, D., & Binder, E. B. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01579-3 · Cited by 38
Copy Number Variation in Subjects with Major Depressive Disorder Who Attempted Suicide
Perlis, R. H., Ruderfer, D., Hamilton, S. P., & Ernst, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046315 · Cited by 29
“Major depressive disorder (MD) is a debilitating illness affecting approximately 5–15% of people in the United States [1], resulting in economic burdens such as lost work days [2] and decreased life expectancy in affected individuals [3].”
BackgroundState of Ireland's mental health: findings from a nationally representative survey
Hyland, P., Vallières, F., Shevlin, M. E., Bentall, R. P., Butter, S., Hartman, T. K., Karatzias, T., Martínez, A. P., McBride, O., Murphy, J., et al. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000312 · Cited by 38
“morbidity), are associated with a marked decrease in life expectancy (Chang et al., 2011) and contribute to the over 800 000 suicide deaths recorded annually (GBD 2017 Causes of Death Collaborators, 2018; GBD, 2022).”
BackgroundSleep-Disordered Breathing and Psychiatric Disorders
Naqvi, H., Wang, D., Glozier, N., & Grunstein, R. R. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0519-z · Cited by 33
Ramsey, C. M., Spira, A. P., Mojtabai, R., Eaton, W. W., Roth, K. B., & Lee, H. B. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.019 · Cited by 28
“…bipolar disorder is associated with an increased risk of all-cause and cause-specific mortality (Osby et al., 2001, Hoyer et al., 2000, Sharma and Markar, 1994, Black et al., 1987a, Laursen et al., 2007, Hoang et al., 2011, Chang et al., 2011, Angst et al., 2002, Tsai et al., 2005, Laursen, 2011).”
BackgroundMethodIoannou, M., Foiselle, M., Mallet, J., Stam, E. L., Godin, O., Dubertret, C., Terro, E., Sommer, I. E., Haarman, B. C. M., Leboyer, M., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.001 · Cited by 28
Associations between symptoms and all-cause mortality in individuals with serious mental illness
Hayes, R. D., Chang, C., Fernandes, A. C., Begum, A., To, D., Broadbent, M. T. M., Hotopf, M. H., & Stewart, R. J. (2011) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2011.09.012 · Cited by 35
Self-citationBartlem, K. M., Bowman, J., Ross, K., Freund, M., Wye, P. M., McElwaine, K., Gillham, K. E., Doherty, E. L., Wolfenden, L., & Wiggers, J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0763-3 · Cited by 36
“A greater prevalence of chronic disease risk behaviours, including tobacco smoking, inadequate nutrition, harmful alcohol consumption, and physical inactivity contribute substantially to this health inequity [1, 2].”
Background
Metadata
- Authors
- Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R.
- Affiliations
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- Corresponding author
- Chang, Chin-Kuo
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-05-18
- Volume
- 6
- Issue
- 5
- Pages
- e19590
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3097201
- OpenAlex
- W2010135111
- Cited by
- 714
- References
- 44
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 42 · 2023: 45 · 2022: 68 · 2021: 54 · 2020: 62 · 2019: 53 · 2018: 54 · 2017: 46 · 2016: 65 · 2015: 50 · 2014: 52 · 2013: 38 · 2012: 24
- FWCI
- 51.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- life expectancy at birth, severe mental illness, mortality gap, premature mortality, schizophrenia, schizoaffective disorder, bipolar disorder, substance use disorders, depressive disorders, years of life lost, sex differences, secondary mental health care, South London and Maudsley NHS Foundation Trust
- MeSH terms
- Adolescent, Adult, Aged, Mental Disorders, Demography, Female, Humans, Life Expectancy, London, Male, Mental Health, Middle Aged, Registries, Wales, Age Distribution, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
